Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial - Wu, Lei; Li, Baisen; Wan, Gang; Wang, Yi; Zhu, Jie; Liang, Long; Leng, Xuefeng; He, Wenwu; Peng, Lin; Han, Yongtao; He, Shuya; Wang, Dongsheng; et al. (Nature communications, 2024)
Keywords: 13/1; 13/21; 13/31; 13/51; 631/67/1059/485; 631/67/1857; 692/4028/67/1059/2325; Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Biomarkers; Carboplatin; Carboplatin - administration & dosage; Carboplatin - therapeutic use; CD11c antigen; CD8 antigen; Chemoradiotherapy - methods; Chemotherapy; Clinical trials; Confidence intervals; Dendritic cells; Disease control; Esophageal cancer; Esophageal carcinoma; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophageal Neoplasms - radiotherapy; Esophageal Neoplasms - therapy; Esophageal Squamous Cell Carcinoma - drug therapy; Esophageal Squamous Cell Carcinoma - mortality; Esophageal Squamous Cell Carcinoma - pathology; Esophageal Squamous Cell Carcinoma - radiotherapy; Esophageal Squamous Cell Carcinoma - therapy; Esophagus; Female; Humanities and Social Sciences; Humans; Immunotherapy; Lymphocytes; Lymphocytes T; Lymphopenia; Macrophages; Male; Medical prognosis; Metastases; Middle Aged; multidisciplinary; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - therapeutic use; PD-1 protein; Progression-Free Survival; Radiation therapy; Safety management; Science; Science (multidisciplinary); Squamous cell carcinoma; Survival; Toxic diseases; Toxicity